# D-ALBA (GIMEMA LAL2116)

Source: https://onco.cc/trials/d-alba/  
OnCo record `d-alba` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that showed Ph-positive ALL can be treated with a pill plus an immunotherapy and no chemotherapy, with 95% of patients alive at 18 months.

## Summary

63 patients (median age 54): molecular response 60% after two blinatumomab cycles rising with further cycles; 18-month OS 95%, DFS 88%; only half went to transplant. NEJM 2020. Four-year update: OS ~80%, DFS ~75%, with IKZF1-plus and T315I relapses. Successor trials (GIMEMA ALL2820 with ponatinib) and MD Anderson ponatinib-blinatumomab series extend the chemotherapy-free approach.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT02744768
- Phase: 2
- Setting: Newly diagnosed Ph-positive ALL, adults of all ages: dasatinib induction followed by blinatumomab, no systemic chemotherapy
- Sponsor: GIMEMA
- Enrolled: 63
- Result: 18-month OS 95%, DFS 88%.
- Outcomes: Overall survival at 18 months: Dasatinib → blinatumomab 95%; Disease-free survival at 18 months: Dasatinib → blinatumomab 88%
- Replication: MD Anderson ponatinib + blinatumomab phase 2 (Jabbour et al.) reproduced near-universal molecular remission without chemotherapy; randomised confirmation (GIMEMA ALL2820, EWALL) pending.

## Sources

- ClinicalTrials.gov NCT02744768: https://clinicaltrials.gov/study/NCT02744768
- NEJM 2020: https://www.nejm.org/doi/full/10.1056/NEJMoa2016272

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)](https://onco.cc/cancers/all-paediatric-ph-positive/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/targets/bcr-abl/), [CD19](https://onco.cc/targets/cd19/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Dasatinib](https://onco.cc/drugs/dasatinib/)
- companies: [GIMEMA](https://onco.cc/companies/gimema/)
- terms: [Ph-positive ALL](https://onco.cc/terms/ph-positive-all/)
- pairings: [BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)](https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/)
- ideas: [Transplant-free Ph-positive ALL for MRD-negative adults](https://onco.cc/ideas/idea-transplant-free-ph-all/)

---
JSON: https://onco.cc/api/v1/entities/d-alba.json